Hologic Inc. (NASDAQ:HOLX) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 3,443,874 shares, a decrease of 23.8% from the October 31st total of 4,517,177 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average daily volume of 3,626,663 shares, the short-interest ratio is currently 0.9 days.

In other news, VP Karleen Marie Oberton sold 31,470 shares of the company’s stock in a transaction on Monday, October 10th. The stock was sold at an average price of $40.00, for a total value of $1,258,800.00. Following the completion of the sale, the vice president now directly owns 17,005 shares in the company, valued at approximately $680,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elaine Ullian sold 18,236 shares of the company’s stock in a transaction on Monday, October 10th. The stock was sold at an average price of $39.88, for a total value of $727,251.68. Following the completion of the sale, the director now owns 42,898 shares of the company’s stock, valued at $1,710,772.24. The disclosure for this sale can be found here. 0.84% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Thompson Siegel & Walmsley LLC boosted its stake in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares in the last quarter. Norinchukin Bank The boosted its stake in Hologic by 0.4% in the second quarter. Norinchukin Bank The now owns 12,724 shares of the company’s stock worth $440,000 after buying an additional 53 shares in the last quarter. US Bancorp DE boosted its stake in Hologic by 0.7% in the second quarter. US Bancorp DE now owns 13,542 shares of the company’s stock worth $468,000 after buying an additional 92 shares in the last quarter. Calvert Investment Management Inc. boosted its stake in Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares in the last quarter. Finally, First Citizens Bank & Trust Co. boosted its stake in Hologic by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 10,559 shares of the company’s stock worth $410,000 after buying an additional 144 shares in the last quarter. 92.95% of the stock is owned by institutional investors and hedge funds.

Shares of Hologic (NASDAQ:HOLX) opened at 38.98 on Wednesday. The company has a market cap of $10.84 billion, a P/E ratio of 33.60 and a beta of 1.13. The firm has a 50-day moving average of $37.85 and a 200 day moving average of $36.89. Hologic has a 52 week low of $31.84 and a 52 week high of $41.66.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. The business earned $726.80 million during the quarter, compared to analysts’ expectations of $721.52 million. Hologic had a net margin of 11.68% and a return on equity of 26.76%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.43 earnings per share. Equities analysts expect that Hologic will post $2.15 EPS for the current fiscal year.

Several equities research analysts have recently commented on HOLX shares. BTIG Research upped their price objective on Hologic from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Thursday, November 3rd. Leerink Swann restated a “top pick” rating and issued a $43.00 price objective (down from $46.00) on shares of Hologic in a research note on Thursday, November 3rd. Zacks Investment Research lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, November 7th. Finally, Barclays PLC upgraded Hologic from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $42.00 to $44.00 in a research note on Friday, September 23rd. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $43.20.

WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of US and international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/short-interest-in-hologic-inc-holx-decreases-by-23-8.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.